At a DHSS meeting regarding AIDs it was stated that new legal restrictions to prevent the dumping of pre-March '83 plasma would have significant practical difficulties. Read more about At a DHSS meeting regarding AIDs it was stated that new legal restrictions to prevent the dumping of pre-March '83 plasma would have significant practical difficulties.
In a letter, Dr Oliver suggested a meeting to discuss blood product supplies and stated that any blood products imported from USA would ideally be made from plasma collected after March 1983. Read more about In a letter, Dr Oliver suggested a meeting to discuss blood product supplies and stated that any blood products imported from USA would ideally be made from plasma collected after March 1983.
Dr Walford considered it possible that concentrates made from the "safer" plasma might be retained for use in the US whilst those older stocks were dumped on export markets such as the UK. Dr Walford also asked if there was any way, perhaps by new labelling requirements to prevent this. Read more about Dr Walford considered it possible that concentrates made from the "safer" plasma might be retained for use in the US whilst those older stocks were dumped on export markets such as the UK. Dr Walford also asked if there was any way, perhaps by new labelling requirements to prevent this.
Dr Walford asked Dr Fowler of Medicines Division whether the supply of blood comprising pre-March plasma could be resisted. Read more about Dr Walford asked Dr Fowler of Medicines Division whether the supply of blood comprising pre-March plasma could be resisted.
In a letter, K.W FItch (Armour) stated that Armour had not preferentially exported plasma stocks out of the USA which had been produced from plasma collected prior to the FDA ruling. Read more about In a letter, K.W FItch (Armour) stated that Armour had not preferentially exported plasma stocks out of the USA which had been produced from plasma collected prior to the FDA ruling.
Professor Bloom wrote to Armour to express concerns that concentrate prepared from plasma collected before March 24 might be preferentially exported from the USA. Read more about Professor Bloom wrote to Armour to express concerns that concentrate prepared from plasma collected before March 24 might be preferentially exported from the USA.
At a meeting of the Blood Products Advisory Committee, Dr Michael Rodell (Armour) indicated that it was clear that pools might have been contaminated. He also stated that persons who were paid for their plasma had it collected 40 to 60 times per year, on average. Read more about At a meeting of the Blood Products Advisory Committee, Dr Michael Rodell (Armour) indicated that it was clear that pools might have been contaminated. He also stated that persons who were paid for their plasma had it collected 40 to 60 times per year, on average.
Professor Sir Michael Rawlins (CSM) stated in his oral evidence that if they had known AIDs was caused by a virus and how donors were pooled in the US, they would have acted differently regarding the importation of commercial factor concentrates. Read more about Professor Sir Michael Rawlins (CSM) stated in his oral evidence that if they had known AIDs was caused by a virus and how donors were pooled in the US, they would have acted differently regarding the importation of commercial factor concentrates.
Professor Sir Michael Rawlins stated in his oral evidence that Dr Galbraith's May 1983 letter and paper should have been provided to the CSM(B). Read more about Professor Sir Michael Rawlins stated in his oral evidence that Dr Galbraith's May 1983 letter and paper should have been provided to the CSM(B).
Professor Sir Michael Rawlins stated that FDA approval was given if the licensing body had found it was appropriate and therefore it carried weight to the product. Read more about Professor Sir Michael Rawlins stated that FDA approval was given if the licensing body had found it was appropriate and therefore it carried weight to the product.